by Richard Daverman, PhD
May 22, 2012 -- More information surfaced about the financing of the high-profile JV being set up by Zhejiang Hisun Pharma and Pfizer. Hisun will contribute a total of $162.5 million for a 51% stake, implying a value of $318.6 million for the venture. The registered capital, however, is listed as $250 million. Hisun may have put in extra capital to nail down a majority stake, but it probably didn’t offer up an extra $70 million for control. More details...
Stock Symbols: (SHA: 600267) (NYSE: PFE)
